Guerbet SA (0ELV.L)
| Previous close | 35.10 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,642 |
| Market cap | 440.59M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 0.14 |
| EPS (TTM) | 2.58 |
| Earnings date | 25 Sept 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Airbus And Two Additional Stocks Estimated To Be Undervalued On Euronext Paris
Amidst a turbulent week for European markets, where political uncertainty and economic indicators painted a mixed picture, investors are keenly observing potential opportunities. In this context, identifying undervalued stocks such as Airbus on the Euronext Paris could be particularly intriguing for those looking to capitalize on discrepancies between current market prices and intrinsic values.
GlobeNewswireGuerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.
Hugues Lecat appointed Chairman of the Board of Directors of Guerbet Villepinte, 24 May 2024: Guerbet (FR0000032526 GBT), a global specialist in contrast products and solutions for medical imaging, is announcing the appointment of Hugues Lecat as Chairman of the Board of Directors, in accordance with the previously announced timetable (press release of 20 March 2024). Following the approval of his appointment as director at the Annual General Meeting held today at the registered office, the Boar
- GlobeNewswire
Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.
NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics -- Agreement brings together Guerbet’s industry leading expertise in medical imaging technologies, production, and commercialization with Nuclidium’s in depth know-how of the copper radioisotope production and theranostic development -- Basel, Switzerland and Villepinte, France, May 22, 2024 – NUCLIDIUM and Guerbet (GBT) today announced a strategic partnership to advance NUCLIDI
